Redx Pharma Plc (REDX.L)

12.75 -0.75 (-5.56%) At close: 06:27PM BST

Redx Pharma Plc

Alderley Park
Block 33 Mereside Alderley Edge
Macclesfield SK10 4TG
United Kingdom
44 16 2546 9900
https://www.redxpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 101

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Lisa Mary Whewell Anson	CEO & Executive Director	608.13k	N/A	1968
Mr. Peter J. Collum	Chief Financial Officer	N/A	N/A	N/A
Dr. James Mead	Chief Operating Officer	132.67k	N/A	1978
Dr. Richard Armer	Chief Scientific Officer	N/A	N/A	N/A
Dr. Karl Hard Ph.D.	Head of Investor Relations	N/A	N/A	1962
Ms. Claire Penelope Solk	General Counsel & Company Secretary	N/A	N/A	N/A
Ms. Caitlin Pearson	Head of Communications	N/A	N/A	N/A
Dr. Cliff Jones	Senior Vice President of Chemistry, DMPK & Intellectual Property	N/A	N/A	N/A
Dr. Caroline Phillips	Senior Vice President of Biology	N/A	N/A	N/A
Mr. Craig Tilston	Head of Development Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Corporate governance

Redx Pharma Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.